Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Firefly Neuroscience, Inc. (AIFF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: AIFF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -87.36% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.84M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.86 - 17.20 | Updated Date 06/16/2025 |
52 Weeks Range 1.86 - 17.20 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4802.33% |
Management Effectiveness
Return on Assets (TTM) -86.34% | Return on Equity (TTM) -860.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37724522 | Price to Sales(TTM) 279.43 |
Enterprise Value 37724522 | Price to Sales(TTM) 279.43 | ||
Enterprise Value to Revenue 271.4 | Enterprise Value to EBITDA - | Shares Outstanding 12861100 | Shares Floating 8202680 |
Shares Outstanding 12861100 | Shares Floating 8202680 | ||
Percent Insiders 40.48 | Percent Institutions 9.56 |
Upturn AI SWOT
Firefly Neuroscience, Inc.
Company Overview
History and Background
Firefly Neuroscience, Inc., founded in 2009, is a neurotechnology company focused on developing objective and quantifiable methods for assessing brain function. It has evolved from research and development to commercializing its brain health assessment platform.
Core Business Areas
- Electroencephalography (EEG): The company's core business is developing and commercializing EEG-based brain health assessment tools. It uses proprietary algorithms and machine learning to analyze EEG data and provide insights into cognitive function, attention, and emotional regulation.
Leadership and Structure
The company is led by a management team with experience in neuroscience, technology, and healthcare. Board members also provide strategic guidance.
Top Products and Market Share
Key Offerings
- Firefly Brain Performance Index (BPI): This is a core product, quantifying cognitive and emotional performance with proprietary EEG-derived biomarkers. It offers objective measurement of brain function. Revenue data is not publicly available. Competitors include companies developing similar neurocognitive testing platforms.
Market Dynamics
Industry Overview
The neurotechnology industry is experiencing growth driven by increasing awareness of brain health and the need for objective diagnostic tools. The market is competitive with both established and emerging companies.
Positioning
Firefly Neuroscience, Inc. is positioned as an innovator in EEG-based brain health assessment. Its competitive advantage lies in its proprietary algorithms and machine learning technology.
Total Addressable Market (TAM)
The TAM for brain health assessment is estimated to be significant, reaching billions of dollars. Firefly Neuroscience is positioning itself to capture a share of this market.
Upturn SWOT Analysis
Strengths
- Proprietary EEG analysis algorithms
- Machine learning capabilities
- Experienced leadership team
- Focus on objective brain health assessment
Weaknesses
- Limited market presence
- Lack of consistent revenue stream
- Regulatory hurdles to market entry
- Dependence on key personnel
Opportunities
- Expanding applications of EEG technology
- Partnerships with healthcare providers
- Increasing awareness of brain health
- Growing market for digital health solutions
Threats
- Competition from established neurotechnology companies
- Rapid technological advancements
- Changing regulatory landscape
- Economic downturn
Competitors and Market Share
Key Competitors
Competitive Landscape
Firefly Neuroscience faces competition from both established and emerging neurotechnology companies. Its success depends on its ability to demonstrate the clinical utility and cost-effectiveness of its products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends cannot be determined due to lack of financial data.
Future Projections: Future projections are not publicly available.
Recent Initiatives: Recent initiatives include continued product development and seeking regulatory approval for its technology.
Summary
Firefly Neuroscience is a neurotechnology company developing EEG-based brain health assessment tools. While it has innovative technology, it faces challenges related to market presence and revenue generation. Its future success depends on strategic partnerships and successful commercialization. Awareness of the importance of brain health will also aid its growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
Disclaimers:
The data provided is based on limited publicly available information and may not be fully comprehensive. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Firefly Neuroscience, Inc.
Exchange NASDAQ | Headquaters Kenmore, NY, United States | ||
IPO Launch date 2011-02-23 | CEO & Director Mr. Greg Lipschitz | ||
Sector Technology | Industry Software - Application | Full time employees 13 | Website https://fireflyneuro.com |
Full time employees 13 | Website https://fireflyneuro.com | ||
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.